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Although AOA1 (ataxia oculomotor apraxia1) is one of the most common 
causes of autosomal recessive cerebellar ataxias in Japanese population, it is 
reported from all over the world. The clinical manifestations are similar to 
ataxia telangiectasia in which non-neurological manifestations are absent and 
include almost 10% of autosomal recessive cerebellar ataxias. Dysarthria and 
gait disorder are the most two common and typical manifestations. Oculomotor 
apraxia is usually seen a few years after the manifestations start. APTX gene 
on 9p13.3 chromosome is expressed in the cells of all human body tissues and 
different mutations had been discovered. Here we report two siblings (a girl and 
a boy) of consanguineous parents visited at Mofid Pediatrics Hospital in 2015, 
with history of gait ataxia, titubation, tremor, and oculomotor apraxia around five 
yr old and after that. The brother showed symptoms of disease earlier and more 
severe than his sister did. After ruling out the common etiologies of progressive 
ataxia, we did genetic study for AOA1 that showed a homozygous frameshift 
mutation as c.418_418 del was found. This mutation was not reported before so 
this was a new mutation in APTX gene.
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introduction
Ataxia with oculomotor apraxia type1 (AOA1) is rare a cause of autosomal 
recessive cerebellar ataxia (ARC) manifested by progressive cerebellar ataxia, 
severe peripheral neuropathy, oculomotor apraxia, and hypoalbuminemia (1-3). The 
diagnosis is based on physical examination, absence of non-neurological signs, the 
progressive nature of disease and the positive familial history (2).
The EMG findings are indicative of a severe sensorimotor axonal neuropathy. The 
oculographic records show” hypo metric saccades, decrease mean gain in amplitude, 
broken saccades into multiple successive saccades and normal latencies” (3). 
Brain MRI shows brain atrophy. Hypercholesterolemia and hypoalbuminemia are 
common (the duration of disease has reverse relation with albumin level and direct 
relation with cholesterol level). The diagnosis is confirmed by molecular analysis of 
APTX gene (3). The differential diagnosis are ataxia telangiectasia, disorders similar 
to ataxia telangiectasia, friedrich ataxia, AOA2, ataxia with vitamin E deficiency 
and spastic AR ataxia Charlevoix-Saguenay. Prenatal tests and carrier testing are 
available for family members if both alleles of disease are known in a family (4).
There is no specific treatment for AOA1 and the treatment is based on supportive 
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procedures including rehabilitation therapy of disabilities 
caused by peripheral neuropathy and cerebellar 
ataxia, educational supporting on reading and writing 
problems, and of course speech therapy of dysarthria 
and cognitive disorders. Low fat and low cholesterol 
diet are recommended. An expert neurologist should do 
routine follow-up. Some experimental therapies such as 
CoQ10 had been tried for assessing the effectiveness of 
treatment (1).
Overall, AOA1 is a progressive neurodegenerative 
disorder and the patients usually lose motor skills and 
become wheel-chair bound 7-10 yr after the disease 
starts.
Case report
Here we report a family with two affected children 
from consanguineous parents visited at Mofid Pediatrics 
Hospital in 2015. The clinical manifestation was 
compatible with AOA1. First (female) child was 17 yr 
old, showed presenting feature at about 5 yr old with 
ataxia, titubation, and dysarthria followed by ocular 
apraxia. In physical examination, she had ataxic gait, 
areflexia, titubation, supranuclear gaze palsy, and 
oculomotor apraxia. Another sibling was a boy that 
showed the same symptoms, but earlier and more severe.
Informed consent was obtained from the parents for 
publication of the case report.
In their family history their aunt (mother’s sister) had 
had this problem; in physical examination, prominent 
finding was ataxic gait, hyporeflexia, downward plantar 
reflex, titubation, oculomotor apraxia, and supranuclear 
gaze palsy. The mental assessment was normal. 
Evaluation for ataxia was done: CBC, TG, Chol, Alb, 
AFP, CEA, CPK, LDH, Aldolase, Ceruloplasmin, 
ammonia lactate, pyruvate, liver function test, HPLC, 
electrophoresis of hemoglobin, vit B12 & vit E level 
was normal. EMG, NCV showed the sign of sensory 
peripheral neuropathy; MRI showed normal finding. 
The genetic study for SCA1, 2, 3, 6, 7 was normal. 
Because of SNGP and ataxia, genetic study for NPC 1, 
2 was performed which was negative. At the last genetic 
study for AOA1 showed a new homozygous frameshift 
mutation in this family.
discussion
AOA1 is caused by a mutation of APTX gene (9p13.3) 
which codes aprataxin and its role is DNA repairment 
(1, 2). Most of the mutations are in fifth, sixth and 
seventh exons. A relation between the genotype and 
phenotype of the disease is proven. For example, severe 
choreic form phenotype is seen in A198V mutation. 
Truncating mutation is accompanied by early onset 
disease and severe intellectual disability phenotype. 
Aprataxin is produced in different human body tissue 
such as muscles, spinal cord, brain and cellular nucleus. 
Different parts of aprataxin repair DNA and RNA. It 
binds to DNA and RNA and makes molecular reactions 
with other repairing proteins. In the site of damage, 
aprataxin changes the damaged ends of DNA and RNA 
and helps them to reconnect.
At least, 30 different mutations causing AOA1 had 
been seen in APTX gene, which most of them make a 
single change in protein structure, block an amino acid 
in aprataxin and produce an abnormal rapid-destroyable 
protein, therefore, the DNA repairing defects (3,4). This 
causes DNA cell accumulation especially in cerebral 
and cerebellar cells, and such accumulations make cell 
apoptosis accelerated and this is specified for motor 
disorders of AOA1(3).
AOA1 is almost 3.6% of all ARCA cases in Portugal (4), 
but it is the most common cause of ARCA in Japan. In a 
cohort study, 227 mostly French patients (158 families) 
with progressive cerebellar ataxia (after Friedrich ataxia 
ruled out) were done in which AOA1 frequency was 
almost 5% (4). In this study, a large group of patients 
were studied with 158 families with non-Friedrich 
progressive ataxia Of 14 cases (9 families) had been 
shown five different types of missense or truncating 
mutations of aprataxin (A198V, d267G, W279X, 
W279R, IVS51). Howover, four new mutations were 
reported. The frequency of AOA1 in this study was 
5%. The mutation careers were assessed in different 
aspects of disease: neurological, neuropsychological, 
electrophysiological, oculographic, biologic, MRI 
findings and physical examination (3).
The disease onset age was 6.8±4.8 (2-18 yr) (3). 
Cerebellar ataxia, atrophy in MRI with severe axonal and 
sensorimotor neuropathy were reported in all patients, 
but hypercholesterolemia (75%), hypoalbuminemia 
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of them had APTX mutation and had AOA1. H201Q (a 
new missense homozygote mutation) in one patient and 
P206L (a Japanese missense mutation) in two patients 
were reported. Heterogeneity in clinical manifestations 
and late onset of disease in comparison of other reports 
were seen in this study (9).
A missense mutation can lead to a late onset of clinical 
manifestations (almost in 9 yr old) nut frameshift or 
nonsense mutation had an onset of 2-12 yr (mean age: 
4.96 yr). Besides, a relation between the mutation and 
the severity of cognitive disorders, dystonia, and chorea 
was found. Cerebellar ataxia, peripheral neuropathy, and 
cerebellar atrophy were most common manifestations. 
Therefore, a new missense mutation in their patients was 
reported (10).
in Conclusion, different clinical phenotypes and 
different multiple mutations had been already found. 
Therefore, in all cases of oculomotor involvements with 
cerebellar ataxia, the diagnosis of AOA1 should be kept 
in mind. Our patients did not have hypoalbuminemia 
and hypercholesterolemia. The MRI was normal. The 
onset age of disease was earlier in frameshift mutations 
coordinated with previous studies but the severity was 
not similar to them. The female patient was 17 yr old 
and was not wheelchair bound yet, but the male patient 
had more severe manifestations and the progression 
should be followed up. They also had new mutations not 
reported already.
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(83%) and oculomotor apraxia (86%) were seen variable 
and were not reported in all patients. The chorea was 
common in the onset of disease (79%), but it disappeared. 
The severe and permanent phenotype of chorea was 
reported with one of a special type of mutation (A198V) 
(3). 
In our research, the onset age of the disease was 5 yr 
in sisters and 3 yr in brothers of the patients, which 
was consistent with the age spectrum of AOA1. Ataxia 
and oculomotor apraxia were seen in both siblings. 
Hypercholesterolemia and hypoalbuminemia were not 
reported. The chorea was more obvious in younger 
patients and cognitive disorders were seen in both 
siblings, however, they were more severe in male 
siblings.
A male patient was reported with AOA1 who was 
homozygotes in G837A, W279X) mutation of APTX. 
The manifestations were seen in 3.5 yr old that were 
atypical: absence of oculomotor apraxia, chorea, and 
cerebellar atrophy. Peripheral neuropathy was shown in 
8 yr old. Cerebellar atrophy was not seen in our study 
even in older patients (5).
A clinical heterogeneity was found in the study in 
patients with early onset ataxia in accompanying by 
hypoalbuminemia). EAOH is a variant of Friedrich 
ataxia in Japan. In the progression of disease, the 
severity of chorea-like movements was decreased and 
hypoalbuminemia became more obvious. Molecular 
analysis showed two missense mutations, one insertion 
mutation and one new missense mutation (6).
A frame shift mutation was reported that had more 
severe phenotype than missense mutations. The relation 
of genotype with early onset ataxia, oculomotor apraxia 
and hypoalbuminemia were under a disagreement and 
challenging atmosphere. Although, frame shift mutations 
were seen in our patients, signs and symptoms were not 
consistent with the genotype mentioned in previous 
studies and it was less severe (7). 
Hypoalbuminemia were seen in 5 Portuguese patients 
during their disease follow-up and they suggested that 
EOCA-HA and AOA1 were same diseases. We have 
seen no hypoalbuminemia and hypercholesterolemia 
during the follow-up of our patients (8). 
Totally, 28 Italian patients were studied who had 
peripheral neuropathy and oculomotor apraxia. Three 
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